Download PDF
Endoscopy 2019; 51(01): 18-29
DOI: 10.1055/a-0644-2495
Original article
© Georg Thieme Verlag KG Stuttgart · New York

Self-expandable metal stent placement for malignant esophageal strictures – changes in clinical outcomes over time

Agnes N. Reijm   *
1   Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
,
Paul Didden   *
1   Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
2   Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands
,
Sara J. C. Schelling
1   Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
,
Peter D. Siersema
3   Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands
,
Marco J. Bruno
1   Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
,
Manon C. W. Spaander
1   Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

submitted 20 November 2017

accepted after revision 17 May 2018

Publication Date:
10 July 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Background Self-expandable metal stents (SEMSs) are effective for improving dysphagia in patients with incurable esophageal cancer but are also associated with recurrent dysphagia and adverse events. In the past decades, new SEMSs have been introduced, but also patients’ risk profiles have altered. It is unknown if these changes have affected SEMS outcomes.

Methods This retrospective cohort study was conducted in a tertiary referral center in the Netherlands. Patients who underwent palliative esophageal SEMS placement for malignant dysphagia between 1994 and 2017 were included. The primary outcome was to assess shifts over time with respect to recurrent dysphagia and adverse events after SEMS placement.

Results 997 patients who underwent SEMS placement were included. Recurrent dysphagia occurred in 309 patients (31 %) and remained stable, although with a trend towards an increase over time (hazard ratio [HR] 1.02 per 1-year increase; P = 0.05). Migration rate significantly increased over time (HR 1.04 per 1-year increase; P = 0.01). SEMS-related complications occurred in 461 patients (46.2 %), with 207 (20.7 %) major and 336 (33.7 %) minor complications. Prior chemoradiotherapy was significantly associated with major complications (HR 1.69; P < 0.001). Pain was the most common adverse event and showed a significant increase over time (P < 0.01). Factors associated with pain were prior chemoradiotherapy, absence of a fistula, axial and radial forces, and squamous cell carcinoma.

Conclusions Despite the introduction of novel esophageal SEMS designs, recurrent dysphagia has not declined over the years. Stent-related complications have increased in recent years, which seems to be mainly associated with more frequent use of chemoradiotherapy prior to SEMS placement.

* Contributed equally to this work.


Table e2, e3, e5

 

  • References

  • 1 Ferlay J, Shin HR, Bray F. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917
    CrossrefPubMedGoogle Scholar
  • 2 Lightdale CJ. Esophageal cancer. American College of Gastroenterology. Am J Gastroenterol 1999; 94: 20-29
    CrossrefPubMedGoogle Scholar
  • 3 Enzinger PC, Mayer RJ. Esophageal cancer. NEJM 2003; 349: 2241-2252
    CrossrefPubMedGoogle Scholar
  • 4 Sagar PM, Gauperaa T, Sue-Ling H. et al. An audit of the treatment of cancer of the oesophagus. Gut 1994; 35: 941-945
    CrossrefPubMedGoogle Scholar
  • 5 Homs MY, Eijkenboom WM, Coen VL. et al. High dose rate brachytherapy for the palliation of malignant dysphagia. Radiother Oncol 2003; 66: 327-332
    CrossrefPubMedGoogle Scholar
  • 6 Sharma P, Kozarek R. Practice Parameters Committee of American College of Gastroenterology.. Role of esophageal stents in benign and malignant diseases. Am J Gastroenterol 2010; 105: 258-273 ; quiz 274
    CrossrefPubMedGoogle Scholar
  • 7 Homs MY, Steyerberg EW, Eijkenboom WM. et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 2004; 364: 1497-1504
    CrossrefPubMedGoogle Scholar
  • 8 Spaander MC, Baron TH, Siersema PD. et al. Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy 2016; 48: 939-948
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Shin JH, Song HY, Ko GY. et al. Esophagorespiratory fistula: long-term results of palliative treatment with covered expandable metallic stents in 61 patients. Radiology 2004; 232: 252-259
    CrossrefPubMedGoogle Scholar
  • 10 Van Heel NC, Haringsma J, Spaander MC. et al. Esophageal stents for the palliation of malignant dysphagia and fistula recurrence after esophagectomy. Gastrointest Endosc 2010; 72: 249-254
    CrossrefPubMedGoogle Scholar
  • 11 Diamantis G, Scarpa M, Bocus P. et al. Quality of life in patients with esophageal stenting for the palliation of malignant dysphagia. World J Gastroenterol 2011; 17: 144-150
    CrossrefPubMedGoogle Scholar
  • 12 Didden P, Spaander MC, Bruno MJ. et al. Esophageal stents in malignant and benign disorders. Curr Gastroenterol Rep 2013; 15: 319
    CrossrefPubMedGoogle Scholar
  • 13 Conio M, Repici A, Battaglia G. et al. A randomized prospective comparison of self-expandable plastic stents and partially covered self-expandable metal stents in the palliation of malignant esophageal dysphagia. Am J Gastroenterol 2007; 102: 2667-2677
    CrossrefPubMedGoogle Scholar
  • 14 Uitdehaag MJ, Siersema PD, Spaander MC. et al. A new fully covered stent with antimigration properties for the palliation of malignant dysphagia: a prospective cohort study. Gastrointest Endosc 2010; 71: 600-605
    CrossrefPubMedGoogle Scholar
  • 15 van Boeckel PG, Repici A, Vleggaar FP. et al. A new metal stent with a controlled-release system for palliation of malignant dysphagia: a prospective, multicenter study. Gastrointest Endosc 2010; 71: 455-460
    CrossrefPubMedGoogle Scholar
  • 16 Siersema PD, Hop WC, van Blankenstein M. et al. A comparison of 3 types of covered metal stents for the palliation of patients with dysphagia caused by esophagogastric carcinoma: a prospective, randomized study. Gastrointest Endosc 2001; 54: 145-153
    CrossrefPubMedGoogle Scholar
  • 17 van Boeckel PG, Siersema PD, Sturgess R. et al. A new partially covered metal stent for palliation of malignant dysphagia: a prospective follow-up study. Gastrointest Endosc 2010; 72: 1269-1273
    CrossrefPubMedGoogle Scholar
  • 18 Verschuur EM, Repici A, Kuipers EJ. et al. New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: a randomized trial. Am J Gastroenterol 2008; 103: 304-312
    CrossrefPubMedGoogle Scholar
  • 19 Uitdehaag MJ, van Hooft JE, Verschuur EM. et al. A fully-covered stent (Alimaxx-E) for the palliation of malignant dysphagia: a prospective follow-up study. Gastrointest Endosc 2009; 70: 1082-1089
    CrossrefPubMedGoogle Scholar
  • 20 Adam A, Ellul J, Watkinson AF. et al. Palliation of inoperable esophageal carcinoma: a prospective randomized trial of laser therapy and stent placement. Radiology 1997; 202: 344-348
    CrossrefPubMedGoogle Scholar
  • 21 Hirdes MM, Vleggaar FP, de Beule M. et al. In vitro evaluation of the radial and axial force of self-expanding esophageal stents. Endoscopy 2013; 45: 997-1005
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Verschuur EM, Steyerberg EW, Kuipers EJ. et al. Effect of stent size on complications and recurrent dysphagia in patients with esophageal or gastric cardia cancer. Gastrointest Endosc 2007; 65: 592-601
    CrossrefPubMedGoogle Scholar
  • 23 Na HK, Song HY, Kim JH. et al. How to design the optimal self-expandable oesophageal metallic stents: 22 years of experience in 645 patients with malignant strictures. Eur Radiol 2013; 23: 786-796
    CrossrefPubMedGoogle Scholar
  • 24 Seven G, Irani S, Ross AS. et al. Partially versus fully covered self-expanding metal stents for benign and malignant esophageal conditions: a single center experience. Surg Endosc 2013; 27: 2185-2192
    CrossrefPubMedGoogle Scholar
  • 25 Shan M, Lu Z, Guo Q. et al. Self-expanding metal stents for palliative treatment of esophageal carcinoma: risk factors for fatal massive bleeding. J Clin Gastroenterol 2012; 46: 758-763
    CrossrefPubMedGoogle Scholar
  • 26 Fuccio L, Scagliarini M, Frazzoni L. et al. Development of a prediction model of adverse events after stent placement for esophageal cancer. Gastrointest Endosc 2016; 83: 746-752
    CrossrefPubMedGoogle Scholar
  • 27 Kinsman KJ, DeGregorio BT, Katon RM. et al. Prior radiation and chemotherapy increase the risk of life-threatening complications after insertion of metallic stents for esophagogastric malignancy. Gastrointest Endosc 1996; 43: 196-203
    CrossrefPubMedGoogle Scholar
  • 28 Lecleire S, Di Fiore F, Ben-Soussan E. et al. Prior chemoradiotherapy is associated with a higher life-threatening complication rate after palliative insertion of metal stents in patients with oesophageal cancer. Aliment Pharmacol Ther 2006; 23: 1693-1702
    CrossrefPubMedGoogle Scholar
  • 29 Homs MY, Hansen BE, van Blankenstein M. et al. Prior radiation and/or chemotherapy has no effect on the outcome of metal stent placement for oesophagogastric carcinoma. Eur J Gastroenterol Hepatol 2004; 16: 163-170
    CrossrefPubMedGoogle Scholar
  • 30 Didden P, Spaander MC, Kuipers EJ. et al. Safety of stent placement in recurrent or persistent esophageal cancer after definitive chemoradiotherapy: a case series. Gastrointest Endosc 2012; 76: 426-430
    CrossrefPubMedGoogle Scholar
  • 31 Dimopoulou I, Galani H, Dafni U. et al. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Cancer 2002; 94: 452-458
    CrossrefPubMedGoogle Scholar
  • 32 Gergel TJ, Leichman L, Nava HR. et al. Effect of concurrent radiation therapy and chemotherapy on pulmonary function in patients with esophageal cancer: dose-volume histogram analysis. Cancer J 2002; 8: 451-460
    CrossrefPubMedGoogle Scholar
  • 33 Bick BL, Song LM, Buttar NS. et al. Stent-associated esophagorespiratory fistulas: incidence and risk factors. Gastrointest Endosc 2013; 77: 181-189
    CrossrefPubMedGoogle Scholar
  • 34 Reijm AN, Didden P, Bruno MJ. et al. Early pain detection and management after esophageal metal stent placement in incurable cancer patients: A prospective observational cohort study. Endosc Int Open 2016; 4: E890-E894
    Article in Thieme ConnectPubMedGoogle Scholar